Ipsen withdraws NDA for rare bone disease treatment less than 3 months after winning priority review
After winning priority review for its ultra-rare bone disease program at the end of May, Ipsen made an abrupt about-face Friday.
Ipsen withdrew its NDA …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
